The Department of Drugs and Food/Essential Drug Bureau (DDF/EDB) has applied and successfully qualified for Global Fund (GF) grant for strengthening health system (HSS) under the National Malaria Control Program (CNM) for the containment of malaria resistant parasites in malaria endemic provinces in Cambodia. The project, Affordable Medicines Facility-malaria (AMFm), as the name suggests, aims at introducing cheaper artemisinin combination therapy (ACTs) in fixed dose combination (FDC) with the aim of driving out of the market oral artemisinin monotherapies and its derivatives which are thought to contribute to the currently observed emergence of malaria parasites tolerant to artemisinin therapy, the only remaining effective and safe medicine for the treatment of uncomplicated malaria caused by Plasmodium falciparum parasite. A large part of DDF work plan under the AMFm project consists of activities that are related to assuring the quality and efficacy of essential medicines; with a particular focus on the long term safety of the new ACTs to patients.